TABLE 2: Drugs and Conditions where the Study Design or Approval was based on Extrapolation from adult trials

|  |  |
| --- | --- |
| Drug Name | Pediatric Condition |
| Dabrafenib (Tafinlar) | adolescent patients with unresectable or metastatic BRAF-V600 mutation positive melanoma |
| Trametinib (Mekinist) | adolescent patients with unresectable and metastatic BRAF-V600 mutant melanoma |
| Ruxolitinib (Jakafi) | adolescent patients with steroid-refractory acute graft versus-  host disease (GVHD) |
| Midostaurin (Rydapt) | pediatric patients with FLT3-mutated acute myeloid leukemia (AML) |
| Nilotinib (Tasigna) | pediatric patients with chronic myelogenous leukemia (CML) |